Advanced Enzyme Technologies Tidigare resultatutveckling
Tidigare kriterier kontrolleras 5/6
Advanced Enzyme Technologies har ökat intäkterna med en genomsnittlig årlig takt på 3.8%, medan Chemicals -branschen såg intäkterna växer på 6.2% årligen. Intäkterna har varit växande med en genomsnittlig takt på 7.4% per år. Advanced Enzyme Technologies s avkastning på eget kapital är 10.3% och den har en nettomarginal på 22.6%.
Viktig information
3.81%
Tillväxttakt i vinsten
3.78%
Tillväxttakt för EPS
| Chemicals Tillväxt i branschen | 17.68% |
| Intäkternas tillväxttakt | 7.40% |
| Avkastning på eget kapital | 10.31% |
| Nettomarginal | 22.62% |
| Senaste uppdateringen av resultatet | 31 Mar 2026 |
Senaste uppdateringar av tidigare prestationer
Recent updates
Uppdatering av berättelse • Jun 18
ADVENZYMES: Stable Case Balances Model Assumptions And Upcoming Dividend Decisions
Analysts have kept their ₹370 price target on Advanced Enzyme Technologies unchanged, citing slightly adjusted assumptions for discount rate, revenue growth, profit margin and future P/E that, in their view, broadly offset each other in the valuation model. Analyst Commentary Recent commentary on Advanced Enzyme Technologies highlights a mix of optimism about the company’s positioning and caution around execution and valuation assumptions, which feeds into how analysts are thinking about the ₹370 target.Uppdatering av berättelse • Jun 01
ADVENZYMES: Steady Cash Assumptions And Upcoming Board Decisions Will Shape Returns
Narrative update on Advanced Enzyme Technologies The analyst price target for Advanced Enzyme Technologies is held steady at ₹370, as analysts point to only very small adjustments in assumptions for discount rate, revenue growth, profit margin and forward P/E after reviewing recent research on comparable companies. Analyst Commentary Recent Street research on other mid-cap service companies has given analysts a reference point as they revisit models for Advanced Enzyme Technologies, even though those reports focus on a different stock.Uppdatering av berättelse • May 12
ADVENZYMES: Stable Margins And Refined Assumptions Will Guide Future Returns
Analysts kept the fair value estimate for Advanced Enzyme Technologies steady at ₹370, citing modest adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions rather than any change in their core outlook. Analyst Commentary Analysts keeping fair value at ₹370 are focusing on how well Advanced Enzyme Technologies can execute on its current plan rather than changing their fundamental view of the stock.Uppdatering av berättelse • Apr 19
ADVENZYMES: Steady Risk And Margins Will Support Future Upside
Analysts have kept their fair value estimate for Advanced Enzyme Technologies steady at ₹370. They cited updated assumptions around the discount rate, growth, margins and future P/E that reflect fine tuning of their models rather than a change in overall conviction.Uppdatering av berättelse • Apr 05
ADVENZYMES: Steady Assumptions And Risk Profile Will Support Future Upside
Analysts have kept the fair value estimate for Advanced Enzyme Technologies steady at ₹370, with only small adjustments to the discount rate, growth, margin and future P/E assumptions informing this unchanged price target. Analyst Commentary Bullish Takeaways Bullish analysts see support for the ₹370 fair value estimate from the decision to keep key model assumptions, such as growth and margins, broadly consistent rather than revising them sharply.Uppdatering av berättelse • Mar 21
ADVENZYMES: Refined Risk Assumptions And Stable Outlook Will Support Upside
Analysts have maintained their fair value estimate for Advanced Enzyme Technologies at ₹370, making small changes to assumptions such as a slightly lower discount rate and marginally adjusted long-term growth and P/E inputs after revisiting their models. Analyst Commentary Bullish Takeaways Bullish analysts see the reaffirmed fair value of ₹370 as supported by refreshed assumptions, suggesting that the refined discount rate and long term inputs still back the existing valuation framework for Advanced Enzyme Technologies.Uppdatering av berättelse • Mar 06
ADVENZYMES: Free Cash Flow Momentum And Cleaner Portfolio Will Drive Upside
Analysts have maintained their fair value estimate for Advanced Enzyme Technologies at ₹370.0 per share, while slightly adjusting assumptions on discount rate, growth, margins and future P/E to reflect updated free cash flow trends and a cleaner portfolio. They expect these factors to support improvement in the second half.Uppdatering av berättelse • Feb 20
ADVENZYMES: Stable Assumptions And Future P/E Reset Will Drive Upside
Analysts have kept their price target for Advanced Enzyme Technologies steady at ₹370, citing largely unchanged assumptions around the discount rate, revenue growth, profit margin and future P/E in their updated models. What's in the News A board meeting is scheduled on January 31, 2026 to consider and approve unaudited financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Uppdatering av berättelse • Feb 05
ADVENZYMES: Future P/E Reset Will Signal Upside Potential For Shares
Analysts have trimmed their fair value estimate for Advanced Enzyme Technologies from ₹440 to ₹370, citing updated assumptions around discount rates, revenue growth, profit margins, and a lower future P/E multiple. What's in the News Board meeting scheduled for January 31, 2026, to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Analysartikel • Jan 31
Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Share Price Not Quite Adding Up
There wouldn't be many who think Advanced Enzyme Technologies Limited's ( NSE:ADVENZYMES ) price-to-earnings (or "P/E...Ny berättelse • Aug 17
Preventive Health And Green Chemistry Will Expand Future Markets
Key Takeaways Expansion into health, wellness, and sustainable enzymatic solutions, along with new B2C initiatives, positions for growth and improved margins as consumer demand rises. International diversification, R&D investment, and increased capacity utilization support long-term product differentiation, earnings stability, and operating leverage.Analysartikel • Aug 04
Here's What's Concerning About Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...Analysartikel • Jun 27
Advanced Enzyme Technologies' (NSE:ADVENZYMES) Dividend Will Be ₹1.20
The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.20...Analysartikel • Jun 12
Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Due To Pay A Dividend Of ₹1.20
The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.20...Analysartikel • Mar 25
Is Advanced Enzyme Technologies (NSE:ADVENZYMES) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysartikel • Aug 20
After Leaping 26% Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Shares Are Not Flying Under The Radar
Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) shareholders have had their patience rewarded with a 26% share...Analysartikel • Jul 19
We Think Shareholders Are Less Likely To Approve A Pay Rise For Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) CEO For Now
Key Insights Advanced Enzyme Technologies' Annual General Meeting to take place on 25th of July Salary of ₹6.69m is...Analysartikel • Jul 13
Advanced Enzyme Technologies (NSE:ADVENZYMES) Has Affirmed Its Dividend Of ₹1.00
The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.00...Analysartikel • Apr 08
Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital Not Reflecting Well On The Business
What are the early trends we should look for to identify a stock that could multiply in value over the long term...Analysartikel • Sep 23
Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Analysartikel • Feb 03
Advanced Enzyme Technologies (NSE:ADVENZYMES) Could Be Struggling To Allocate Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? In a perfect world...Analysartikel • Aug 11
Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...Analysartikel • May 13
With EPS Growth And More, Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Interesting
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...Analysartikel • Mar 28
Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES) Paint A Concerning Picture
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll...Fördelning av intäkter och kostnader
Fördelning av intäkter och kostnader
Hur Advanced Enzyme Technologies tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.
Resultat- och intäktshistorik
| Datum | Intäkter | Intäkter | G+A Kostnader | FoU-kostnader |
|---|---|---|---|---|
| 31 Mar 26 | 7,458 | 1,687 | 1,623 | 0 |
| 31 Dec 25 | 7,096 | 1,522 | 1,658 | 0 |
| 30 Sep 25 | 7,067 | 1,474 | 1,590 | 0 |
| 30 Jun 25 | 6,683 | 1,369 | 1,552 | 0 |
| 31 Mar 25 | 6,369 | 1,311 | 1,501 | 0 |
| 31 Dec 24 | 6,275 | 1,329 | 1,460 | 0 |
| 30 Sep 24 | 6,194 | 1,371 | 1,434 | 0 |
| 30 Jun 24 | 6,311 | 1,386 | 1,394 | 0 |
| 31 Mar 24 | 6,239 | 1,333 | 1,355 | 0 |
| 31 Dec 23 | 6,048 | 1,371 | 1,327 | 0 |
| 30 Sep 23 | 5,859 | 1,248 | 1,296 | 0 |
| 30 Jun 23 | 5,668 | 1,166 | 1,257 | 0 |
| 31 Mar 23 | 5,406 | 1,056 | 1,217 | 0 |
| 31 Dec 22 | 5,337 | 979 | 1,167 | 0 |
| 30 Sep 22 | 5,251 | 960 | 1,131 | 0 |
| 30 Jun 22 | 5,135 | 995 | 1,111 | 0 |
| 31 Mar 22 | 5,294 | 1,196 | 1,099 | 0 |
| 31 Dec 21 | 5,309 | 1,268 | 1,040 | 0 |
| 30 Sep 21 | 5,350 | 1,424 | 1,000 | 0 |
| 30 Jun 21 | 5,325 | 1,500 | 930 | 0 |
| 31 Mar 21 | 5,018 | 1,459 | 898 | 0 |
| 31 Dec 20 | 4,820 | 1,459 | 891 | 0 |
| 30 Sep 20 | 4,569 | 1,364 | 868 | 0 |
| 30 Jun 20 | 4,481 | 1,301 | 859 | 0 |
| 31 Mar 20 | 4,440 | 1,293 | 852 | 0 |
| 31 Dec 19 | 4,480 | 1,302 | 871 | 0 |
| 30 Sep 19 | 4,366 | 1,210 | 900 | 0 |
| 30 Jun 19 | 4,288 | 1,148 | 891 | 0 |
| 31 Mar 19 | 4,220 | 1,111 | 888 | 0 |
| 31 Dec 18 | 4,194 | 1,061 | 873 | 0 |
| 30 Sep 18 | 4,261 | 1,068 | 838 | 0 |
| 30 Jun 18 | 4,199 | 1,039 | 737 | 0 |
| 31 Mar 18 | 3,918 | 901 | 752 | 0 |
| 31 Dec 17 | 3,660 | 837 | 687 | 0 |
| 30 Sep 17 | 3,213 | 725 | 624 | 0 |
| 30 Jun 17 | 3,127 | 793 | 592 | 0 |
| 31 Mar 17 | 3,290 | 915 | 546 | 0 |
| 31 Dec 16 | 3,260 | 942 | 536 | 0 |
| 30 Sep 16 | 3,404 | 998 | 521 | 0 |
| 30 Jun 16 | 3,184 | 854 | 489 | 0 |
| 31 Mar 16 | 2,938 | 759 | 486 | 0 |
Kvalitetsintäkter: ADVENZYMES har inkomster av hög kvalitet.
Växande vinstmarginal: ADVENZYMES s nuvarande netto vinstmarginaler (22.6%) är högre än förra året (20.6%).
Fritt kassaflöde vs resultatanalys
Analys av tidigare vinsttillväxt
Resultatutveckling: ADVENZYMES s intäkter har ökat med 3.8% per år under de senaste 5 åren.
Accelererande tillväxt: ADVENZYMES s intäktstillväxt under det senaste året ( 28.7% ) överstiger sitt 5-åriga genomsnitt ( 3.8% per år).
Resultat vs industri: ADVENZYMES vinsttillväxt under det senaste året ( 28.7% ) översteg Chemicals branschen 13.6%.
Avkastning på eget kapital
Hög ROE: ADVENZYMES s avkastning på eget kapital ( 10.3% ) anses vara låg.
Avkastning på tillgångar
Avkastning på sysselsatt kapital
Upptäck starka bolag som tidigare presterat bra
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/06/19 16:58 |
| Aktiekurs vid dagens slut | 2026/06/19 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2026/03/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Advanced Enzyme Technologies Limited bevakas av 4 analytiker. 1 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Nandan Chakraborty | Axis Capital Limited |
| Abhishek Navalgund | Centrum Broking Limited |
| null null | DBS Bank Ltd |